Entry level $121 = Target price $134 = Stop loss $117
Nice gap fill trade setup, as the market has turned slightly bullish after earnings announcement by GWPH
MACD about to cross above zero line, short cover signal.
RSI has room to run higher, alert set for 78 level.
Short interest = 18.64% could fuel a nice rally
Average Recommendation: BUY Average Target Price:201
15 BUY
00 OVERWEIGHT
00 HOLD
00 SELL
Company profile
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, IT IS REALLY APPRECIATED
Nice gap fill trade setup, as the market has turned slightly bullish after earnings announcement by GWPH
MACD about to cross above zero line, short cover signal.
RSI has room to run higher, alert set for 78 level.
Short interest = 18.64% could fuel a nice rally
Average Recommendation: BUY Average Target Price:201
15 BUY
00 OVERWEIGHT
00 HOLD
00 SELL
Company profile
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, IT IS REALLY APPRECIATED